Tyrosine kinase inhibitors

From Libre Pathology
Revision as of 15:14, 20 October 2014 by Michael (talk | contribs)
Jump to navigation Jump to search

Tyrosine kinase inhibitors, abbreviated TKIs, are a group of drugs that inhibit the action of tyrosine kinases.

The category includes many cancer drugs - including:

  • Imatinib (Gleevec).
  • Gefitinib (Iressa).
  • Erlotinib (Tarceva).

Others - used in RCC:[1]

  • Sunitinib (Sutent).
  • Sorafenib (Nexavar).
  • Pazopanib (Votrient).

Use

See also

References

  1. ↑ URL: http://dtb.bmj.com/content/49/11/129.abstract. Accessed on: 3 October 2014
  2. ↑ Song, Z.; Lin, B.; Shao, L.; Zhang, Y. (Sep 2013). "Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.". J Chin Med Assoc 76 (9): 481-5. doi:10.1016/j.jcma.2013.05.007. PMID 23769878.
Retrieved from "https://librepathology.org/w/index.php?title=Tyrosine_kinase_inhibitors&oldid=34261"